Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Study Suggests Minor Cannabinoids Could Treat Skin Ailments

Recent research suggests that lesser-known cannabinoids derived from marijuana and hemp, such as CBN, CBM, CBC, CBDV and THCV, might hold promise in treating dermatological conditions INCLUDING acne, psoriasis and eczema. The study, published recently in the peer-reviewed journal “Molecules,” highlights the potential therapeutic value of these minor cannabinoids in managing skin disorders as well as presenting new avenues for patient care and well-being enhancement.

The research, led by Polish scholars Dorota Kowalczuk and Emilia Kwiecień, involved an extensive review of existing scientific literature. The team observed that minor cannabinoids exhibit a range of pharmacological activities, encompassing anti-itch, analgesic, antimicrobial and anti-inflammatory properties. These cannabinoids have also shown efficacy in alleviating symptoms linked to various dermatological issues, including pruritus, acne, eczema and psoriasis.

Some minor cannabinoids appeared particularly suited for targeting specific skin conditions. For instance, CBDV, due to its anti-inflammatory characteristics, can potentially soothe itching and inflammation related to atopic dermatitis. Additionally, its antioxidant properties could aid in healing acne lesions.

Similarly, other recently identified cannabinoids such as CBE and CBM display anti-inflammatory potential and open new avenues for research into targeted disease conditions. CBC, known for its anti-inflammatory and antioxidant effects, may offer benefits for treating psoriasis, acne and atopic dermatitis.

THCV stands out for its potential in combating acne because it appears to regulate sebum production. Its anti-inflammatory and antibacterial attributes contribute to alleviating inflammation and targeting bacteria linked to acne development.

The researchers highlighted the therapeutic potential of minor cannabinoids, including cannabinol (CBN), cannabigerol (CBG), cannabigerolic acid (CBGA), tetrahydrocannabivarin (THCV), cannabichromene (CBC), cannabidiforol (CBDP) and cannabidivarin (CBDV), as well as newer discoveries such as cannabielsoin (CBE) and cannabimovone (CBM).

The effects are believed to stem from interactions between cannabinoids and the body’s endocannabinoid system, a central regulatory mechanism crucial for maintaining organism health and function. This system plays a pivotal role in regulating skin functions, immune responses, cell differentiation, proliferation and survival, thereby effectively mitigating skin inflammation. Furthermore, topical application of these minor cannabinoids may hold promise for mitigating aging-related effects on the skin.

However, the researchers caution that more in-depth research is essential to validate their safety and effectiveness. Multiple challenges, including impact on the nervous system, product quality and regulation concerns, and ethical and legal considerations, need comprehensive exploration.

They concluded that despite the encouraging therapeutic potential, the utilization of cannabinoids, particularly minor ones, requires continued research, stringent regulations and a balanced approach to maximize benefits while minimizing any potential risks to health and society.

Companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) selling marijuana for both medical and recreational use could be helping people combat more symptoms or conditions than the patients themselves intend.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes What Is Considered One Of America’s Most Serious Health Problems

  • The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year95% of Americans with diabetes are diagnosed with type 2 diabetes, which can lead to heart disease, stroke, kidney damage, and nerve damage when left untreatedLexaria’s DIAB-A22-1 pre-clinical diabetes study using DehydraTECH(TM)-CBD in obese diabetic-conditioned animals shows promising results, prompting the company to investigate for human trial

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical trial to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss. The company’s pre-clinical diabetes study, DIAB-A22-1, in obese diabetic-conditioned animals, provided successful results and has driven Lexaria’s management to investigate whether animal improvements will be evidenced in humans.Diabetes can impact various parts of the body, including the heart, kidneys, eyes, feet, and legs. The longer a person lives with the condition at high blood sugar levels, the more serious complications can become. Diabetes is manageable, but its impact on overall health is often underestimated.According to the American Diabetes Association (“ADA”), 37.3 million Americans reported having diabetes in 2019. Of those 37.3 million, 28.7 million were diagnosed, and 8.5 million were not. Each year, the ADA reports an additional 1.4 million Americans are diagnosed with diabetes (https://cnw.fm/5ZFeZ). When left untreated, diabetes can lead to complications, including heart disease, stroke, kidney damage, and nerve damage. “Non-alcoholic fatty liver disease (‘NAFLD’), which doctors historically have diagnosed in adults, is rapidly increasing in children, driven by the obesity epidemic” (https://cnw.fm/ImCtn).More than 95% of the people diagnosed with diabetes fall into the category of Type 2 diabetes, which affects how the body uses sugar for energy. Over time, type 2 diabetes can cause serious damage to the body if it is not managed. Often preventable, factors that contribute to the development of type 2 diabetes are obesity, lack of exercise, and genetics (https://cnw.fm/sgqWK).Lexaria designed DehydraTECH for formulating and delivering lipophilic drugs and active pharmaceutical ingredients. The benefits of DehydraTECH include faster drug delivery times, increased bioavailability, increased brain absorption, higher drug potency, reduced drug administration costs, masking tastes, and reduced use of sugars.DehydraTECH is suitable for various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, topicals, and over-the-counter pills, capsules, tablets, and oral suspensions. Lexaria has already shown value in the hypertension and nicotine pouch industries through the use of its DehydraTECH formulations.Lexaria’s DIAB-A22-1 study in obese diabetic-conditioned animals utilized its DehydraTECH-CBD formulation, which showed an ability to reduce animal blood sugar levels – warranting additional investigation. Lexaria reported:

  • Lowered blood glucose levels by 19.9% (p<0.05)Lowered overall body weight by 7% sustained over eight weeksWitnessed a statistically significant increase in locomotor activity (p<0.05)Lowered triglyceride levels by more than 25% (p<0.007)Lowered blood urea nitrogen levels by 27.9% (p<0.001)

The company is very interested in discovering if a similar formulation might effectively control human blood sugar levels – strongly suggesting that DehydraTECH-CBD may be a potential solution for treating diabetes and its complications in humans.Lexaria intends to conduct the study, which is currently being designed, at the same medical research hospital in Europe that it used for its recent human clinical hypertension studies. The cost-effective approach allows Lexaria to complete the most research possible at a fraction of the cost of US-based registered study programs. Once the study has been designed and approved, Lexaria will provide additional information, including timelines and study details, as they become available.For more information, visit the company’s website at www.LexariaBioscience.com.NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXXAbout CannabisNewsWireCannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)For more information, please visit https://www.CannabisNewsWire.comPlease see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/DisclaimerCannabisNewsWireDenver, COwww.CannabisNewsWire.com303.498.7722 OfficeEditor@CannabisNewsWire.comCannabisNewsWire is powered by IBN

420 with CNW — Marijuana Legalization Voter Initiative Text Gets Nod from Ohio Officials

Officials in Ohio have approved language for a measure that would appear on the November 2023 ballot giving voters the chance legalize marijuana in the state. The Ohio Ballot Board unanimously approved a recently drafted and certified summary from the secretary of state’s office in a meeting that saw no discussion of the legislation’s text or testimonies from supporters and opponents.

State officials announced two weeks ago that the activists behind the Ohio cannabis legalization measure had collected enough valid signatures to qualify the proposed legislation for the November ballot. A statement from Secretary of State Frank LaRose’s office revealed that the Coalition to Regulate Marijuana Like Alcohol (CTRMLA) ultimately submitted 127,772 valid signatures, around 3,000 more than the number required by state law.

The summary approved by the Ohio Ballot Board indicated that the proposal would legalize and regulate cannabis cultivation, processing, purchasing, home cultivation and consumption by adults aged 21 years and older. It would also allow the possession of up to 15 grams of cannabis concentrates, up to 2.5 ounces of cannabis, cultivation of up to 6 cannabis plants for one individual’s personal use, and up to 12 plants max per home.

Furthermore, the summary stated that the measure would require the formation of a Division of Cannabis Control to regulate and penalize recreational cannabis operators, testing laboratories and people who require cannabis-related licenses. It also noted that the adult-use cannabis measure would create a social equity program, sustain landlords’ and employers’ rights to ban cannabis use in specific circumstances, and tax cannabis sales revenue.

The measure would channel cannabis tax revenue to different accounts, offer protections for financial institutions that serve licensed cannabis businesses and protect the identities of individuals taking part in the recreational cannabis market.

CRMLA spokesperson Tom Haren noted in a recent statement that the measure would provide hundreds of millions of dollars in new tax revenue and the same level of regulation seen in the medical marijuana market. According to Haren, the campaign is looking forward to eliminating Ohio’s cannabis black market once official sales begin.

Since cannabis has been the most consumed illegal drug in the United States for years, a massive black market is supplying the country’s immense demand for marijuana. Even now that more than 20 states have recreational cannabis markets, America’s illicit cannabis market still supplies most of the country’s cannabis, undercutting state-legal adult-use programs, funding criminal enterprises and harming the environment.

If Ohio voters choose to legalize cannabis in the upcoming ballot vote, the legal recreational market will likely have a hard time competing with the illicit market. However, major cannabis players, such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), in different markets have always found a way to attract customers, so the licensed players in Ohio will thrive as best they can once the recreational market launches.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — DOJ Asks FBI to Investigate Itself After Cannabis Arrest Data Errors Are Found

After more than a year, a watchdog from the Justice Department responded to a lawyer’s concerns about issues in how the FBI gathers and reports data related to marijuana possession arrests. The response, however, was not a direct addressing of the problem but a suggestion that the FBI should internally investigate the matter.

Eric Sterling, a lawyer known for his work in drug-policy reform and a former congressional aide, sent a letter to the Department of Justice’s Office of the Inspector General in May last year. In his letter, Sterling highlighted a situation where a police department in Maryland was categorizing citations for cannabis possession under the state’s decriminalization law as arrests. This data was being shared with the FBI, potentially leading to skewed statistics and a distorted view of law enforcement’s focus and the implementation of legalization and decriminalization policies.

Sterling, an appointed member of the Policing Advisory Commission for Montgomery County, Maryland, urged the DOJ inspector general’s office to initiate a formal investigation into this matter.

After approximately 14 months, the OIG investigations division responded to Sterling’s inquiry. Instead of directly addressing the issue, division officials indicated that another department within the DOJ would be better suited to review the concerns. They subsequently referred the matter to the FBI’s inspection division.

Sterling expressed concern that the delayed response signified a lack of capacity within the DOJ’s investigative body, potentially compromising its ability to handle more serious cases of misconduct. The delay is noteworthy because it could impact the accuracy of the FBI’s annual uniform crime report. With more than a year already passed, there’s a risk that the report will continue to inaccurately represent the changes in cannabis policy happening across the nation.

This situation is particularly relevant in areas that have decriminalized marijuana, where possession might lead to civil penalties but is not meant to result in an arrest. By wrongly categorizing these instances as arrests, the impact of policy changes could be understated or even misrepresented as an increase in crime.

Furthermore, the reliability of the FBI’s cannabis enforcement reporting is questionable because local and state police aren’t obligated to share their data with the agency. This results in an incomplete overview of law enforcement activities on a national scale. The latest quarterly report had data from only 12,518 out of 18,900 law enforcement agencies in the country.

Despite these reporting concerns, recent trends have generally aligned with expectations. The FBI’s data shows a decrease in cannabis-related arrests as more states have embraced legalization. Even the DEA reported fewer marijuana-related arrests in the previous year, while the agency’s eradication of cannabis plants increased.

Customs and Border Protection data from the past fiscal year also revealed a record low in cannabis seizures. A report from the Government Accountability Office echoed these trends, illustrating that enforcement activities are primarily targeting small amounts of marijuana possessed by U.S. citizens rather than large shipments from international sources.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Alternative Products Expo: Innovation and Sustainability

Financial analysts, savvy investors, business owners, researchers, and pioneers, are invited to attend Alternative Products Expo to be held at the World Market Center, Las Vegas from September 14-16, 2023. Las Vegas plays host to thousands of esteemed events every year, and there are several reasons for this: state-of-the-art hospitality, top-notch facilities, year-round sunshine, and world-class dining and entertainment options. Featuring one-of-a-kind nightlife, the city never fails to provide a memorable experience for the attendees.

Alternative Products Expo (AltPro Expo) promises to deliver unique networking opportunities for customers and businesses alike. The highly anticipated event has earned a reputation for offering an incredible platform for business owners to showcase their unique and sustainable products. As the countdown for this innovative Expo begins, attendees can expect an unmatched experience packed with actionable insights from the industry leaders.

Exciting Opportunities for Forward-Thinking Businesses

Pioneered by a group of socially responsible entrepreneurs, the Alternative Products Expo is committed to connecting revolutionary businesses with health-conscious customers. The expo will feature a wide range of eco-friendly and innovative products, ranging from plant-based foods, and renewable energy technologies, to sustainable packaging solutions and ethical fashion items. They will witness innovative demos and learn of the latest product launches that will shape a sustainable future and reduce the environmental footprint at a global level.

The AltPro Expo provides customers with a unique opportunity to buy products that contribute to an eco-friendly planet. The organizers will implement sustainable practices throughout the Expo to ensure the targeted audience aligns with their values. Attendees will get a unique opportunity to network with like-minded entrepreneurs and potential investors who will share their passion for innovation. By attending thought-provoking seminars and panel discussions, they will get insights into the latest trends and best practices in the alternative products industry.

To learn more, please visit https://cnw.fm/A8zIE.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Psychosis-Prone Young People Registered Surprising Symptom Improvement After Using Marijuana

A team of researchers from several institutions has discovered that cannabis may improve symptoms in teenagers and young adults at risk of developing psychosis. The study contradicts claims that marijuana use can trigger the early onset of psychotic disorder symptoms and shows that cannabis may actually deliver modest cognitive functioning improvements while reducing the use of prescribed medications.

Researchers at the Stanford University School of Medicine, Zucker Hillside Hospital, University of California at Davis and the University of Michigan published their findings in the “Psychiatry Research” journal. The study noted that the recent surge in recreational cannabis use has raised questions regarding the possibility of adult use being a trigger for the onset of psychosis.

However, the study authors note that there is little evidence tying cannabis use and negative health outcomes for people who are predisposed to developing psychosis.

The research team followed 210 patients with a clinical high risk (CHR) of psychosis who took part in an Early Detection and Intervention for the Prevention of Psychosis Program (EDIPPP) for two years. Over the study period, the researchers compared prescription medication use with mental health in people who consumed cannabis regularly and people who didn’t consume cannabis.

Individuals who consumed cannabis continually over the two-year study period did not exhibit an increased psychosis transition rate, study authors say, and cannabis use did not contribute to a decline in clinical symptoms, neurocognition or functioning levels. On the contrary, youth who used cannabis continuously exhibited improved clinical symptoms even as their medication use decreased.

Furthermore, the scientists found that CHR youth who used cannabis regularly over the study period had higher social functioning and neurocognition compared to noncannabis users. The recent study adds to the growing body of scientific literature on cannabis and its potential association with psychosis.

Cannabis legalization opponents have long claimed that cannabis use can trigger schizophrenia, especially now that the market is flooded with increasingly potent THC-infused products. Some medical professionals have also stated that continued exposure to high-THC cannabis may cause psychosis-like symptoms in some consumers.

Studies have found that cannabis-induced psychosis is quite rare, with a Canadian study that analyzed 23,000 consumers finding that only 26 individuals required hospitalization for psychotic-like symptoms. Data from Canada also shows that although the country legalized adult-use cannabis in 2018, there has been no significant increase in the number of emergency room visits due to cannabis-induced schizophrenia or psychosis.

Additionally, a European study published in the “Translation Psychiatry” journal found that less than one-half of 1% of 230,000 consumers experienced psychosis-like symptoms after consuming cannabis.

As the different misconceptions about marijuana are dispelled one at a time, demand for the substance is likely to increase and enterprises such as Advanced Container Technologies Inc. (OTC: ACTX), which capitalize on availing some of the products that marijuana cultivators need, could grow their businesses.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — How Cannabis Can Help with Oral Health

Cannabis has attracted a lot of attention in recent years due to its potent and rather versatile therapeutic properties. States with medical cannabis programs allow patients suffering from at least one out of more than 20 qualifying conditions to use cannabis for therapeutic purposes, indicating marijuana’s wide range of medical applications.

Furthermore, researchers are constantly working to further cannabis science and understand precisely how it delivers its benefits to develop safe cannabis-derived medications for various health issues. Surprisingly, cannabis may also have some applications in oral health, particularly in terms of managing dental pain and anxiety.

It is a known fact that cannabis can be effective against chronic pain. A large portion of recreational users and medical cannabis patients use the plant to address pain-related conditions. Furthermore, researchers have noted a possible reduction in opioid prescriptions in states with legal cannabis markets as people turn to cannabis as an alternative for pain relief.

This makes cannabis a possible option for alleviating pain caused by dental issues. The Centers for Disease Control and Prevention (CDC) estimates that more than 40% of U.S. adults experience some kind of dental pain every year. In extreme cases, dental pain can cause or exacerbate mental issues, including depression, and significantly reduce an individual’s quality of life. Although cannabis may be a temporary solution to most dental issues, it has the ability to inhibit pain of most kinds and could be helpful in treating dental pain.

Cannabis extract CBD (cannabidiol) is specifically known for its pain-relieving properties, especially when paired with another extract called THC (delta-9 tetrahydrocannabinol). CBD also has anti-inflammatory and antioxidant properties that could make it effective at treating and promoting the healing of common dental conditions like canker sores.

Some cannabinoids have antibacterial properties that could allow for the development of cannabis-based products to minimize the effects of dangerous oral bacteria and reduce the risk of oral diseases. On top of that, marijuana’s anti-anxiety effects at low doses can also help to alleviate the anxiety many people feel before a dentist appointment.

Around 36% of Americans are estimated to have a fear of dental treatment, and 12% report having an extreme fear of dental treatments. Given how important regular dental appointments are to maintaining dental health and overall physical and mental health, it is crucial that everyone visits a dentist at least once every year for a checkup.

For people with anxiety prior to dentist visits, cannabis can help alleviate their anxiety, calm their fears and allow them to successfully complete dental exams.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Registration for Medical Marijuana Cards in South Dakota Nearly Doubles State Projections

More than two years have passed since the legalization of medical cannabis in South Dakota, and an impressive count of more than 11,500 individuals from the state now possess medical marijuana cards. This substantial figure stands in stark contrast to the initial projections made back in 2021 when the program was launched, as Jennifer Seale, the medical cannabis program administrator at the state Department of Health, pointed out.

Initially, the state had envisaged a cardholder count of 6,000 by 2024, a projection that Seale shared with the members of the Medical Cannabis Oversight Committee in Pierre during a recent session. The committee, composed of lawmakers and other officials, evaluates the state-operated medical cannabis program and provides suggestions for its enhancement.

The fiscal year 2023 witnessed a significant portion of the medical cannabis program’s revenue attributed to newly issued cards, amassing a total of $1.37 million. However, Seale expressed uncertainty about the sustainability of this revenue stream once the issuance of medical cannabis cards reaches a saturation point.

A contentious issue that emerged in discussions pertains to pop-up clinics, which have become a primary channel through which South Dakotans access medical cannabis cards. The issue of pop-up clinics was also flagged as problematic during a prior committee assembly in October 2022. This concern led to the introduction of failed bills, one of which aimed to confine medical cannabis clinics to specific facilities.

Representative Fred Deutsch presented these bills during the legislative session of 2023, which concluded in March. Reflecting on his personal experience of acquiring a medical cannabis card, Deutsch underscored the lack of privacy due to audibly overheard conversations between patients and providers. Additionally, he highlighted the suboptimal nature of the provider-patient relationship established during the appointment. Deutsch’s appointment was conducted by a nurse practitioner he had not encountered before. He criticized the appointment for its brevity, lasting less than 10 minutes, and for failing to conduct a thorough examination to determine his eligibility for the card.

The committee is poised to readdress the issue, potentially through legislation or recommendations presented to the Legislature. Several ideas are under consideration, including barring individuals with vested interests in the cannabis industry from operating pop-up clinics, mandating ongoing medical education for card issuance and implementing a cap on the number of cards a provider can issue in a single day.

Although the fee for obtaining a medical cannabis card remains at $75, pop-up clinics have the latitude to impose significantly higher charges for appointments. As Deutsch disclosed, he paid around $170 for his appointment.

Presently, there is no limitation on the number of cards a provider can dispense. Senator Erin Tobin, who chairs the committee, asserted that enforcing such a change would eliminate the financial incentive associated with operating pop-up clinics.

The committee’s discussions extended to other matters, including the utilization of medical cannabis by parolees, even though substances such as alcohol are prohibited for them. Some members of the committee contended that this allowance contradicts the court’s intention of barring parolees from alcohol or drug use. The committee has plans to revisit the topic of pop-up clinics and other associated issues in its forthcoming meeting.

The growing interest in the medical use of marijuana could encourage many companies such as Advanced Container Technologies Inc. (OTC: ACTX) to expand their operations and address the growing demand for cultivation equipment and other supplies needed in the marijuana value chain.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Why Canadian MJ Companies Are Increasingly Flagging Each Other for Noncompliance

An escalating number of Canadian marijuana enterprises are submitting grievances against their industry counterparts, alleging infractions or expressing concerns. This escalating trend is a product of fierce rivalry and struggling companies resorting to any available advantage, as experts point out.

According to Canada’s federal marijuana regulatory authority, the past year witnessed 706 instances of such grievances filed by regulated marijuana establishments against fellow regulated operators. This figure represents a notable surge compared to the records from 2021, which documented 214 formal complaints, and the statistics from 2020, when the count stood at 182 complaints, as data from Health Canada showed.

Chad Finkelstein, a legal expert at the Toronto-based law firm Dale and Lessmann, commented on the situation, noting that “numerous cannabis enterprises engage in various marketing practices that border on regulatory conformity or, in some instances, overtly violate them.”

In a recent example, an Alberta-based cannabis retailer was found to have transgressed the advertising criteria laid out by the province’s Cannabis, Liquor, and Gaming Commission. Finkelstein noted that previously, cannabis companies habitually scrutinized each marketing concept in advance to ensure compliance. However, fewer firms follow this practice today. He suggested this shift might be due, in part, to the historical lack of enforcement against potentially contentious marketing actions, leading marijuana companies to perceive these as permissible.

Finkelstein, who also chairs the firm’s marijuana division, advised companies to heed feedback from the public. “The optimal approach to risk mitigation involves avoiding platforms more likely to attract family or parental attention,” he advised. “We’ve encountered clients who desired to take calculated risks with advertising during festivals or via mailers potentially seen by minors. If your target audience includes families, there’s a higher likelihood of receiving grievances compared to instances where exposure to children is limited, and parents are less predisposed to field inquiries from their children regarding the presence and meaning of the content.”

Hyde Advisory and Investments CEO David Hyde affirmed that there is an increasing number of distressed licensed producers, resulting in heightened complaints lodged against rival enterprises. He noted that licensed producers struggling to differentiate themselves often resort to questionable measures to gain an edge over competitors.

“Many are forced to navigate advertising restrictions, skirt sampling limitations, or even offer incentives to retailers — whatever it takes, as many have realized that pushing boundaries and taking risks is essential,” he said.

This has prompted their competitors, which are also teetering on the brink, to cry foul, even if they aren’t actually breaching regulations or crossing boundaries, simply because they are just as desperate.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

NECANN’s 4th Annual New Jersey Cannabis Convention Is The Perfect Setting to Learn Everything about the Cannabis Industry

The largest B2B cannabis industry event in New Jersey – NECANN’s New Jersey Cannabis Convention – returns to Atlantic City on September 8-9, 2023. Now in its 4th year, the event, which is part of the largest cannabis and hemp convention series in the world, continues to grow as the New Jersey cannabis market develops. It comes more than a year after the state legalized the sale of recreational marijuana, which led to the April 2023 opening of the first licensed recreational marijuana dispensary in Atlantic City (https://cnw.fm/KVDTv).

With such stores finally opening and the number of licenses rapidly increasing, the number of ancillary businesses, entrepreneurs, investors, cultivators, medical dispensaries, license holders, and suppliers, is increasing by the day. Conveniently, NECANN’s New Jersey Cannabis Convention is designed for this category of budding industry players and entrants, among others. The event represents everything that touches cannabis and promises to be the perfect setting for attendees to learn about the industry.

“There’s everything here that you could possibly learn about the cannabis industry. Everything from grow lights, payment processors, banking, [and] accounting. If you are looking to start any type of cannabis business, you can come to NECANN and learn whatever you are trying to learn,” said Brian O’Connor of Paybotic, a payment processor that enables cannabis businesses to transact, in a video recapping the 2021 event (https://cnw.fm/HJvmM).

What makes the New Jersey Cannabis Convention particularly appealing to startups is the fact that it is an opportunity to meet similar sprouting businesses. Even so, the event is equally suited for exhibitors drawn from every niche within the cannabis industry. Attracting thousands of cultivators, industry professionals, educators, and advocates, from hundreds of local and national companies, the New Jersey Cannabis Convention promises a lot of foot traffic, much to the advantage of vendors and businesses showcasing their products. In fact, exhibitors who were part of previous editions of the event have lauded its role in bringing them closer to investors and potential business partners. The 2023 event will be no different, so reserve your exhibit space today.

For attendees in pursuit of knowledge, there’s more! The activity-packed two-day event features learnings from expert speakers delivered through dozens of planned sessions. Moreover, there are plenty of networking opportunities. The New Jersey Cannabis Convention is the perfect setting to learn, meet, and network. So do not miss it – register today.

For more information, please visit https://cnw.fm/DiUCt

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.